Isomorphic Labs secures US$2.1B funding to scale AI drug discovery

USA—AI-driven drug discovery company Isomorphic Labs has raised US$2.1 billion in Series B financing as it accelerates efforts to move its artificial intelligence-powered drug development platform from research into large-scale clinical applications.

The investment marks one of the largest funding rounds in the AI healthcare sector and reflects growing investor confidence in AI’s ability to transform pharmaceutical research and development.

The funding round was led by Thrive Capital and included participation from existing investors Alphabet and GV, alongside new backers CapitalG, MGX, Temasek, and the UK Sovereign AI Fund.

The company said the latest financing significantly strengthens its international investor base while expanding support for its long-term growth strategy.

Expanding AI-powered drug development

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

The platform integrates several advanced AI models to predict biological structures, identify promising drug candidates, and accelerate discovery across multiple therapeutic areas and drug modalities.

The company also intends to accelerate its pipeline of therapeutic programmes toward clinical-stage development.

In addition, it will expand hiring efforts by recruiting more specialists in artificial intelligence, clinical research, drug design, and engineering across its global sites.

Max Jaderberg, president of Isomorphic Labs, said the company’s AI engine has already demonstrated its effectiveness through internal programmes that reached important development milestones at unprecedented speed.

He added that the platform provides a repeatable method for designing new medicines across a wide range of diseases.

Founder and CEO Sir Demis Hassabis described the investment as a major endorsement of the company’s AI-first approach to drug discovery.

According to Hassabis, the new financing will enable Isomorphic Labs to scale its technology infrastructure and accelerate its mission to develop treatments for complex diseases.

Strategic partnerships and industry momentum

The company has continued to strengthen its position in the pharmaceutical sector through collaborations with major drugmakers, including Novartis, Johnson & Johnson, and Eli Lilly and Company.

These partnerships support the development of AI-designed medicines and validate the commercial potential of Isomorphic Labs’ technology platform.

Recent publications and company updates also highlighted improvements in IsoDDE’s predictive capabilities, particularly in protein structure prediction and molecular interaction modelling.

The technology builds on advances linked to AlphaFold, the groundbreaking AI system developed within Google DeepMind that transformed protein structure prediction in biomedical research.

The company now expects its first AI-designed drugs to enter clinical trials by the end of 2026, slightly later than earlier projections.

Industry analysts view the timeline as part of the broader challenge of translating AI-generated discoveries into clinically validated therapies.

Isomorphic Labs previously raised US$600 million in external funding in 2025 to support its AI-driven drug discovery programmes and expand its operational footprint globally.